Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Galapagos NV

Market Cap 163.69Cr 189.52Cr 189.52Cr 150.84Cr 141.19Cr 264.6Cr 18TCr 268.7Cr 1.78TCr 694.42Cr 8.77TCr 711.27Cr 696.13Cr 30TCr P/E Ratio 2026 *
-10.8x
P/E Ratio 2027 * -9.93x
Enterprise Value -116.59Cr -134.99Cr -134.99Cr -107.44Cr -100.56Cr -188.46Cr -13TCr -191.38Cr -1.27TCr -494.6Cr -6.25TCr -506.6Cr -495.82Cr -22TCr EV / Sales 2026 *
-6.44x
EV / Sales 2027 * -4.97x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 13/05/2025
Director of Finance/CFO 43 07/07/2025
Chief Tech/Sci/R&D Officer 61 08/06/2026
Director TitleAgeSince
Director/Board Member 64 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 13/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%+0.97%-15.96%-12.73% 4.3TCr
+2.91%+3.02%+273.97%+507.43% 3.17TCr
-0.21%-1.40%+13.67%-14.64% 3.02TCr
+1.65%-2.13%-4.40%+23.99% 2.89TCr
+4.09%-1.98%+11.99%+17.37% 2.39TCr
-1.34%+3.28%+54.32%+115.19% 1.36TCr
-0.40%-1.29%+6.06%+7.59% 1.3TCr
+2.38%+5.15% - - 1.34TCr
-0.92%-1.93%+105.05%+75.45% 1.22TCr
Average +0.86%-0.71%+55.59%+89.96% 2.33TCr
Weighted average by Cap. +0.99%-1.08%+54.35%+95.71%

Financials

2026 *2027 *
Net sales 18Cr 21Cr 21Cr 17Cr 16Cr 29Cr 1.99TCr 30Cr 197.07Cr 77Cr 970.16Cr 79Cr 77Cr 3.36TCr 18Cr 21Cr 21Cr 16Cr 15Cr 29Cr 1.95TCr 29Cr 193.04Cr 75Cr 950.32Cr 77Cr 75Cr 3.29TCr
Net income -24Cr -27Cr -27Cr -22Cr -20Cr -38Cr -2.59TCr -39Cr -256.49Cr -100Cr -1.26TCr -102.43Cr -100.25Cr -4.37TCr -14Cr -17Cr -17Cr -13Cr -12Cr -23Cr -1.59TCr -24Cr -156.98Cr -61Cr -772.82Cr -63Cr -61Cr -2.68TCr
Net Debt -280.28Cr -324.51Cr -324.51Cr -258.27Cr -241.76Cr -453.07Cr -31TCr -460.08Cr -3.05TCr -1.19TCr -15TCr -1.22TCr -1.19TCr -52TCr -251.86Cr -291.6Cr -291.6Cr -232.09Cr -217.24Cr -407.13Cr -28TCr -413.44Cr -2.74TCr -1.07TCr -13TCr -1.09TCr -1.07TCr -47TCr
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!